What Regeneron Pharmaceuticals Doubters Got Wrong
Regeneron Pharmaceuticals has seen a 25.9% increase in investor returns over the past year, outperforming bearish analyst predictions. Despite some setbacks like a failed melanoma trial, the company's FDA approvals for Livsayis and strong Q3 2026 revenues for Dupixent and EYLEA HD have largely validated the bullish outlook. The current stock price of US$923 reflects an assumption that product and partnership wins will continue to outweigh pricing and pipeline challenges.
Regeneron Pharmaceuticals, Inc. (REGN) Options Chain - Yahoo Finance
This article presents the options chain for Regeneron Pharmaceuticals, Inc. (REGN) as of 11:04:34 a.m. EST. It details various call and put options with different strike prices, last prices, changes, percentage changes, volumes, and open interests. The stock's current price is listed at 928.85, showing a +0.70% increase, and it also notes a recently announced cash dividend.
MRNA - Moderna Will Revolutionize Cancer Vaccines With Intismeran and Merck. But the market has already priced in a lot of success
Moderna is transitioning from a COVID-vaccine company to a cancer-vaccine company, with its intismeran cancer vaccine (developed with Merck) showing promise, particularly in melanoma. While this new therapy offers significant market potential, the stock's substantial increase from $24 to $203 suggests that much of this success is already factored into its current price. Risks include regulatory hurdles, the full efficacy data not yet being released for Phase 3 trials, competition from BioNTech, and ongoing cash burn.
Regeneron Pharmaceuticals falls 2.35% in Thursday's session
Regeneron Pharmaceuticals' shares declined by 2.35% to $923.34 on November 19, 2026, in the United States health care sector. The company's market capitalization stood at $95.12 billion. This report is automatically generated based on market data, reflecting the last traded price rather than the official closing price.
Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance
Sanofi and Regeneron have both achieved significant rare disease approvals, with Sanofi's Infilbray targeting neurological symptoms of type 3 Gaucher disease and Regeneron's Livsayis entering the generalized myasthenia gravis market. Meanwhile, Eli Lilly continues its aggressive dealmaking, announcing cancer research collaborations and acquisitions totaling billions, even as its popular GLP-1 weight loss drugs face increasing safety concerns and regulatory scrutiny. The article also touches on Moonshot AI's pivot towards scientific R&D, highlighting the growing intersection of AI and biopharma despite governance challenges.
Sanofi Weighs Takeover of Insmed; INSM Stock Surges 21% in Biggest Day Since August
Insmed Inc. (INSM) shares surged 21% after a report indicated Sanofi SA (SNY) is exploring a possible acquisition of the rare-disease drugmaker. Sanofi, under new CEO Belén Garijo, is looking for late-stage and commercial assets in immunology, rare diseases, and vaccines to bolster growth ahead of its Dupixent patent cliff. This potential deal, which could value Insmed at around $31 billion, would be one of the largest biopharmaceutical acquisitions in recent years.
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
The FDA has approved Livsayis (cemdisiran), Regeneron's first siRNA therapy, for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment is administered four times a year and showed rapid and deep disease control in the Phase 3 NIMBLE trial. The approval marks Regeneron's entry into the neurology medicine market, offering a new treatment option for patients with this rare autoimmune disease.
Regeneron breaks into neurology with FDA nod in crowded myasthenia gravis
The FDA has approved Livsayis (cemdisiran), Regeneron's siRNA drug licensed from Alnylam, for adults with generalized myasthenia gravis (gMG). This marks Regeneron's first foray into neurology and its first small interfering RNA approval, despite entering an increasingly competitive gMG market. Livsayis is notable for being the first siRNA therapy for gMG to silence the C5 gene in the liver and for its unique subcutaneous administration four times a year, though challenges remain regarding healthcare provider administration and potential self-administration expansion for market uptake.
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
Regeneron and Alnylam Pharmaceuticals have received FDA approval for Livsayis (cemdisiran), their first siRNA therapy for generalized myasthenia gravis (gMG). This marks Regeneron's second new modality approval this year, following a gene therapy for hearing loss in April. Livsayis offers a "first-in-class" treatment option for gMG, providing best-in-class efficacy with convenient quarterly subcutaneous dosing.
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
The FDA has approved Livsayis, Regeneron's first RNA interference (RNAi) drug, for generalized myasthenia gravis, an autoimmune disease. Developed in collaboration with Alnylam, Livsayis is an RNAi therapy that targets the C5 protein and will compete with established medicines from AstraZeneca and Argenx. Despite a list price of $410,000 per year and initial skepticism from some analysts due to a competitive market, others are optimistic about its best-in-class efficacy and convenient quarterly subcutaneous injection, projecting peak annual sales of $1.5 billion.
Regeneron stock rating held at Buy by TD Cowen on gMG approval
TD Cowen reiterated a Buy rating and a $980 price target on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) following the FDA approval of Cemdi as Livsayis for generalized myasthenia gravis (gMG). The firm expects Livsayis to gain adoption due to its efficacy and quarterly subcutaneous dosing, projecting global peak sales of $1.5 billion, and sees potential upside to its 20% peak share estimate in switch patients. Regeneron also reported strong Q3 earnings, driven by Dupixent, prompting several other analysts to raise their price targets.
Truist reiterates Buy on Regeneron stock after FDA approval
Truist Securities reiterated a Buy rating and a $982.00 price target for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) following FDA approval of Livsayis (cemdisiran) for generalized myasthenia gravis. The approval marks Regeneron's first approved siRNA and neurology medicine, featuring a differentiated quarterly subcutaneous dosing schedule. This new treatment, along with the company's existing commercial portfolio, is expected to continue outperforming analyst estimates.
Form 4 Regeneron Pharmaceuticals Inc: Andrew J. Murphy (Co-Chief Scientific Officer) For: 16 November
This article reports on a Form 4 filing for Regeneron Pharmaceuticals Inc, concerning Andrew J. Murphy, their Co-Chief Scientific Officer, for activities on November 16. Form 4 filings detail changes in the beneficial ownership of company stock by insiders. The article indicates a market response with Regeneron's stock symbol REGN showing a slight decrease.
Form 4 Regeneron Pharmaceuticals Inc: Andrew J. Murphy (Co-Chief Scientific Officer) For: 16 November
This article reports on a Form 4 filing for Regeneron Pharmaceuticals Inc., detailing a transaction by Andrew J. Murphy, the Co-Chief Scientific Officer, on November 16. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders. This disclosure provides transparency regarding executive stock transactions.
Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
Biohaven's novel FGFR3-directed antibody-drug conjugate (ADC), BHV-1530, demonstrated promising clinical activity and confirmed responses in patients with FGFR3-altered urothelial cancer (UC) and head and neck squamous cell carcinoma (HNSCC) in an ongoing Phase 1 study. Data presented at ENA 2026 showed deep and durable responses, including in patients who failed prior standard-of-care therapies, with BHV-1530 being well tolerated and free from common FGFR tyrosine kinase inhibitor toxicities. Biohaven plans to initiate a pivotal study in FGFR3-altered tumors, starting with UC, in the first half of 2027 to support potential accelerated approval.
Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
Biohaven Ltd. announced positive Phase 1 clinical data for BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC), showing deep and durable responses in patients with FGFR3-altered urothelial cancer and HPV-positive head and neck squamous cell carcinoma. The drug was well-tolerated, with no FGFR class toxicities observed. Biohaven plans to initiate a pivotal study in FGFR3-altered tumors, starting with urothelial cancer, in the first half of 2027 to support potential accelerated approval.
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
Regeneron Pharmaceuticals announced that new and updated data from its hematology portfolio and pipeline will be presented across 14 abstracts at the American Society of Hematology (ASH) 2026 Annual Meeting. Key presentations include primary analysis from a potentially pivotal trial of Ordspono® (odronextamab) in relapsed/refractory marginal zone lymphoma and new data on Lynozyfic® (linvoseltamab) in relapsed/refractory systemic light chain (AL) amyloidosis. The company will also highlight progress in bispecific antibodies and novel siRNA therapies for various blood cancers and disorders.
Texas awarded cancer grants to 12 projects from 207 applications; Marker received $16.2 million.
Marker Therapeutics (MRKR) has been awarded a $16.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This non-dilutive funding will advance the company's MT-601 (neldaleucel) therapy into a Phase 2 APOLLO study for patients with relapsed or refractory large B-cell lymphoma following CD19-directed CAR-T therapy. The grant was part of a highly competitive funding cycle where CPRIT received 207 applications and awarded $74.3 million to 12 projects.
VRTX - Vertex Pharmaceuticals Inc Volatility & Greeks
This article provides a detailed financial overview of Vertex Pharmaceuticals Inc (VRTX), including its latest stock performance, market capitalization, earnings per share, and various financial ratios. It also highlights insider and institutional ownership, short interest, and analyst recommendations, offering a comprehensive snapshot of the company's financial health and market position.
Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
The FDA has approved Regeneron Pharmaceuticals' Livsayis (cemdisiran) for generalized myasthenia gravis (gMG) in adults with anti-acetylcholine receptor antibodies. This makes Livsayis the first and only FDA-approved siRNA therapy for gMG, administered subcutaneously four times a year, targeting complement component factor 5 to reduce terminal complement activation. The approval was based on positive Phase 3 NIMBLE trial results showing rapid and sustained symptom relief.
FDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALS
The FDA has approved Regeneron's New Drug Application (NDA 221251) for LIVSAYIS (cemdisiran), a new molecular entity, on November 18, 2026. The approval was granted under a priority review for the 189 mg/mL single-dose vial. This significant regulatory clearance marks a positive development for shareholders, indicating a new drug has passed FDA scrutiny.
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA...
The FDA has approved Livsayis (cemdisiran) by Regeneron Pharmaceuticals for adults with anti-AChR antibody-positive generalized myasthenia gravis (gMG). This marks the first siRNA therapy for gMG and the only treatment administered subcutaneously four times a year. Clinical trials demonstrated significant improvements in MG-ADL and QMG scores compared to placebo, though the drug carries a Boxed Warning for serious meningococcal infections and is subject to a restricted REMS program.
FDA approves Regeneron's Livsayis, a four-times-a-year injection for generalized myasthenia gravis
The FDA has approved Regeneron's Livsayis (cemdisiran) for adults with generalized myasthenia gravis who are anti-AChR antibody positive. This siRNA drug is injected four times a year, a unique schedule among approved treatments, and is Regeneron's first approved neurology medicine. The approval is based on the NIMBLE trial results showing significant improvement in daily living and muscle function scores, although the drug carries a boxed warning for serious meningococcal infections.
In four trades on Nov. 16, a CareDx (CDNA) director sold 5,285 shares under a preset trading plan.
CareDx, Inc. (CDNA) director Richard Bryan Riggsbee sold a total of 5,285 shares of common stock on November 16, 2026, across four separate transactions. These sales were executed under a Rule 10b5-1 trading plan that was adopted on August 4, 2026, with weighted-average prices ranging from $74.0181 to $77.0225 per share. Following these transactions, Riggsbee's direct holdings in CareDx common stock decreased from 39,312 to 34,027 shares.
At $2.35 a share, the COO of Alto Neuroscience (ANRO) exercised options. He also sold shares.
Alto Neuroscience, Inc.'s COO, Michael Conick Hanley Jr., exercised options for 75,000 shares at $2.35 per share and subsequently sold these 75,000 shares between November 16 and November 18, 2026. The transactions were executed under a Rule 10b5-1 trading plan established on August 14, 2026. Weighted-average sale prices for the shares ranged from $26.48 to $29.0863 over the three days.
US FDA approves Regeneron’s drug for generalized myasthenia gravis
The US FDA has approved Regeneron Pharmaceuticals' drug, Livsayis (cemdisiran), for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. Livsayis is an RNA-silencing therapy administered quarterly, marking Regeneron's first approved medicine in both siRNA and neurology fields. The drug carries a boxed warning for meningococcal infections, requiring vaccination before treatment.
At Cytokinetics (CYTK), the CEO exercised options at $10.60 a share and sold 7,500 shares the same day.
Cytokinetics (CYTK) CEO Robert I. Blum exercised options for 7,500 common shares at $10.60 per share on November 16, 2026. On the same day, he sold these 7,500 shares in three tranches at weighted-average prices of $53.22, $54.08, and $55.21. These transactions were executed under a Rule 10b5-1 plan, and his option position after the exercise was 126,745 shares.
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA...
The FDA has approved Livsayis™ (cemdisiran) as the first and only siRNA therapy for adult patients with anti-AChR antibody-positive generalized myasthenia gravis, and the only treatment offering four-times-a-year subcutaneous dosing. This approval, based on the Phase 3 NIMBLE trial, adds a neurology product to Regeneron's portfolio, showing statistically significant improvements in MG-ADL and QMG scales. The drug carries a Boxed Warning for serious meningococcal infections and is available through a restricted REMS program.
A $2.36-a-share purchase brought the CEO of Eagle Point Credit Co (ECC) to 52,000 directly held common shares.
Thomas P. Majewski, CEO of Eagle Point Credit Co (ECC), purchased 50,000 common shares at $2.36 each on November 18, 2026. This acquisition increased his direct holdings to 52,000 common shares, with additional indirect holdings through Majewski Family 2022 Holdings LLC and various preferred shares. The transaction was reported via an SEC Form 4 filing and did not involve a Rule 10b5-1 plan.
Regeneron Pharmaceuticals Director Sold Shares Worth Over $1.9M
George L. Sing, a director at Regeneron Pharmaceuticals (REGN), sold a total of 2,000 shares of company stock on November 16 and 17, 2026, for over $1.9 million. These transactions involved sales at weighted average prices of $960.26 and $957.69 per share. Following the sales, Sing's direct and indirect holdings in the company were reduced to 23,147 directly owned shares and additional shares held by his spouse and through a trust.
The day after exercising options on 17,000 Regeneron (REGN) shares, Andrew J. Murphy sold stock.
Andrew J. Murphy, Co-Chief Scientific Officer at Regeneron Pharmaceuticals (REGN), sold 5,011 common shares on November 17, 2026, for prices between $949.69 and $964.36, following an options exercise for 17,000 shares on November 16, 2026. The transactions were conducted under a Rule 10b5-1(c) plan adopted in May 2026, with a portion of the exercised shares withheld for tax liabilities. After these transactions, Murphy holds 46,779 direct common shares and 4,414 indirect shares through a 401(k) Plan.
Sanofi's pill becomes first US-approved drug for rare neurological disorder
The U.S. FDA has approved Sanofi's oral drug venglustat, branded as Infilbray, as the first treatment for type 3 Gaucher disease, a rare neurological disorder. This approval marks a significant step for Sanofi in reducing its reliance on Dupixent and offers a treatment that can cross into the brain to address cognitive and motor symptoms. The drug works by lowering the production of fatty substances, differing from previous enzyme replacement therapies.
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
Regeneron Pharmaceuticals (REGN) has received European Commission (EC) approval for a more flexible dosing schedule for its cancer drug, Libtayo, across all six approved indications. This approval allows for a higher 700 mg dose every six weeks and shorter infusion times, aiming to enhance patient convenience and strengthen Libtayo's market position. The company is also seeking similar approval in the U.S., with a decision expected in March 2027.
US FDA approves Regeneron’s drug for generalized myasthenia gravis
The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals' drug for treating adults with generalized myasthenia gravis. The approval applies to patients who test positive for anti-acetylcholine receptor antibodies. Regeneron announced the approval on Thursday.
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Regeneron Pharmaceuticals Inc. (REGN) shares fell 1.28% to $945.53 on Wednesday, despite a poor overall trading session for the stock market, with both the S&P 500 and Dow Jones Industrial Average also declining. The company's stock closed 4.66% below its 52-week high of $991.73, which was reached on November 4th.
A Regeneron cancer-drug project hits a pre-human milestone, triggering $5 million for CytomX.
CytomX Therapeutics announced the achievement of a preclinical milestone in its collaboration with Regeneron, leading to a $5 million payment to CytomX. This milestone marks the first under the partnership, which began in 2022 and expanded in June 2026. The collaboration aims to develop conditionally activated bispecific antibodies for cancer treatment, with CytomX eligible for up to approximately $4 billion in potential payments and tiered royalties.
Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD
Visara, a subsidiary of NovaBridge Biosciences, has dosed the first patient in its ASCEND Phase 2b trial for VIS-101, a potential treatment for wet age-related macular degeneration (wet AMD). The head-to-head study in China, partnered with Everest Medicines, aims to evaluate the efficacy, safety, and durability of VIS-101 against aflibercept, focusing on its potential to enable extended treatment intervals. Previous Phase 2a results showed promising durability, with about 50% of treatment-naïve patients remaining retreatment-free six months after the last loading dose.
NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)
NanoViricides, Inc. has announced the filing of its Quarterly Report, highlighting that its broad-spectrum antiviral drug, NV-387 Oral Gummies, has entered two Phase II clinical trials. One trial is for the treatment of Ebola Bundibugyo Virus Disease, for which there is currently no licensed drug or vaccine, and the other is for Mpox (Monkeypox). The company also reported significant progress in its Measles drug program, receiving Orphan Drug and Rare Pediatric Disease Drug designations for NV-387, and detailed its financial position and future funding needs for advancing its clinical development pipeline.
FDA approves Novartis's Cosentyx for polymyalgia rheumatica, the first IL-17 drug for the disease
The FDA has approved Novartis's Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica (PMR) who have an inadequate response to steroids or cannot tolerate tapering, marking it as the first IL-17 drug for the disease and Cosentyx's 11th US indication. The approval was based on the REPLENISH trial, where 40.5% of patients on Cosentyx 150 mg achieved sustained remission compared to 20.5% on placebo. Cosentyx is Novartis's top-selling drug, with third-quarter sales of $1.857 billion, and this PMR indication is already approved in the European Union.
Data on Purple Biotech's experimental cancer candidate gets a main-stage medical conference slot Nov. 20.
Purple Biotech (NASDAQ/TASE: PPBT) reported a third-quarter net loss of $981,000, a decrease from $1.305 million in the prior year, attributed to lower operating expenses. The company also announced that data for its lead experimental cancer candidate, IM1240, will be presented in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026. Purple Biotech expects its current cash and equivalents to fund operations through late 2027 and plans to submit an Investigational New Drug application for IM1240 in 2027.
After a $20.4M sale, Regeneron (REGN) director George L. Sing proposes selling 1,000 more shares.
Regeneron Pharmaceuticals, Inc. director George L. Sing has proposed selling an additional 1,000 common shares, valued at approximately $957,687.10, with an approximate sale date of November 17, 2026. This proposed sale follows two recent insider transactions where Sing sold 1,000 shares for $960,264.40 on November 16, 2026, and 21,129 shares for $20,376,359.76 on November 2, 2026. The SEC filing, Form 144, reports 101,630,713 common shares outstanding for Regeneron.
CytomX to receive $5M from Regeneron for cancer drug milestone (CTMX:NASDAQ)
CytomX Therapeutics is set to receive a $5 million payment from Regeneron after achieving a preclinical milestone in their cancer drug development partnership. Following this announcement, CytomX shares experienced a 4.6% increase in extended trading. This payment highlights progress in the collaboration between the two companies.
CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
CytomX Therapeutics announced the achievement of a preclinical milestone in its collaboration with Regeneron, triggering a $5 million payment. This collaboration focuses on developing conditionally activated bispecific antibodies that target the tumor microenvironment, aiming to improve the therapeutic window and reduce side effects of T-cell engaging therapies. The partnership, which began in 2022 and expanded in June 2026, has the potential for CytomX to receive up to approximately $4 billion in milestone payments and tiered royalties.
CytomX Therapeutics Announces $5 Million Preclinical Milestone Payment Under Regeneron Collaboration
CytomX Therapeutics announced it will receive a $5 million preclinical milestone payment from Regeneron, signaling progress in their 2022 collaboration, which was expanded in June 2026. This partnership focuses on developing bispecific antibodies using CytomX's PROBODY® technology and Regeneron's Veloci-Bi® platform, aiming to create cancer therapies that activate specifically in tumor environments to reduce side effects. Under the agreement, CytomX is eligible for up to $4 billion in potential milestone payments and royalties from future product sales.
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval
Regeneron Pharmaceuticals anticipates continued revenue growth driven by its key products, EYLEA HD, LIBTAYO, and DUPIXENT, despite increasing R&D spending and planned launches in new specialty areas. The company is optimistic about securing U.S. approval for an EYLEA HD prefilled syringe by year-end, which is expected to boost adoption. Regeneron is also actively defending its EYLEA HD patents, which could provide exclusivity into the late 2030s or 2040s, while exploring early-stage opportunities in liver disease, ovarian cancer, and POTS.
Dr Reddy's v Boehringer Ingelheim: empagliflozin SPC falls for lack of plausibility
The Patents Court has invalidated Boehringer Ingelheim's basic patent for empagliflozin, the active ingredient in its diabetes drug Jardiance, due to a lack of plausibility that the compound would inhibit SGLT. This ruling also causes the supplementary protection certificate (SPC) to fall. However, a separate patent claiming a crystalline form of empagliflozin was upheld as valid.
Research updates, November 17
This article summarizes key findings from two recent conferences focusing on Long COVID and postural orthostatic tachycardia syndrome (POTS). Early results showed Regeneron's baloncibart improved heart rate and orthostatic intolerance in POTS patients, while an IVIG trial for Long COVID-related POTS had null results. The conferences also highlighted ongoing research into biomarkers, genetics, and clinical care approaches for Long COVID.
REGN: Q3 growth was strong as pipeline investment and EYLEA HD expansion shape the outlook
Regeneron Pharmaceuticals (REGN) reported strong Q3 revenue and non-GAAP EPS growth, primarily driven by EYLEA HD, LIBTAYO, and DUPIXENT. The company's future strategy focuses on advancing pipeline programs, increasing R&D investment, and pursuing disciplined business development. A key upcoming milestone is the decision on EYLEA HD's prefilled syringe, targeted for year-end 2026.
CRISPR Therapeutics CEO Sam Kulkarni says investors are "sleeping on gene editing" as one-shot therapy takes on siRNA
CRISPR Therapeutics CEO Sam Kulkarni argues that gene editing is transitioning from a scientific endeavor to a commercial product, with Casgevy generating significant revenue and a pipeline of promising assets. Kulkarni asserts that gene editing's one-and-done approach will ultimately outperform chronic dosing economically, even as the company diversifies into siRNA assets to generate short-term catalysts. He highlights the mechanistic and health-economic advantages of gene editing, suggesting that payers may prefer upfront costs over decades of chronic treatment.
European Commission approves flexible dosing for Regeneron’s Libtayo By Investing.com
The European Commission has approved a flexible dosing schedule for Regeneron Pharmaceuticals Inc.'s Libtayo (cemiplimab) across its approved cancer indications. This allows patients to receive a 700 mg dose every six weeks after an initial 12 weeks of treatment, and potentially reduces infusion times, aiming to ease the burden of frequent clinic visits. A similar application for this alternative dosing regimen is currently under review in the United States, with a decision anticipated in March 2027.